- US-listed companies
- Edesa Biotech, Inc.
- Income statement
Edesa Biotech, Inc. (EDSA) Income statement
Market cap
$60.61M
P/E ratio
| 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Revenue | 758,689 | 1 | 228,287 | 211,849 | 328,801 | - | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | |||
| Cost of revenue | 580,824 | 818,566 | 250,042 | 133,316 | 17,601 | - | - | - | - | - |
| Research & development | 1 | 2 | 2 | 2 | 3 | 18 | 13 | 5 | 3 | 4 |
| Operating margin (%) | - | - | - | - | - | - | ||||
| Operating expenses | 5 | 6 | 5 | 5 | 7 | - | - | - | - | - |
| Operating income | - | -4,908,356 | -5,224,546 | -5,078,250 | -6,400,842 | -23,681,332 | -18,370,790 | -9,222,758 | -7,014,744 | -7,911,566 |
| Income before tax | -2,806,229 | -5,018,880 | -5,029,848 | -5,038,149 | - | - | -17,548,124 | -8,373,615 | -6,169,245 | -7,184,723 |
| Pretax margin (%) | -369.9 | -394.7 | -2,203.3 | -2,378.2 | - | - | - | - | - | - |
| Provision for income taxes | 36,800 | 7,200 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 |
| Effective tax rate (%) | - | - | ||||||||
| Net income | -2,843,029 | -5,026,080 | -5,030,648 | -5,038,949 | -6,364,230 | -13,342,350 | 18 | 8 | -6 | -7 |
| Net income margin (%) | - | - | - | - | - | |||||
| Earnings per share | -0.36 | -0.57 | - | - | - | - | - | - | -1.93 | -1.27 |
| Diluted EPS | -0.36 | -0.57 | - | - | - | - | - | - | -1.93 | -1.27 |
| EBITDA | - | - | - | - | - | - | ||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - |